These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

199 related articles for article (PubMed ID: 38797570)

  • 1. Emerging paradigms and recent progress in targeting ErbB in cancers.
    Stoup N; Liberelle M; Lebègue N; Van Seuningen I
    Trends Pharmacol Sci; 2024 Jun; 45(6):552-576. PubMed ID: 38797570
    [TBL] [Abstract][Full Text] [Related]  

  • 2. New Directions for Advanced Targeting Strategies of EGFR Signaling in Cancer.
    Zhou Y; Takahashi JI; Sakurai H
    Biol Pharm Bull; 2024; 47(5):895-903. PubMed ID: 38692865
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Therapeutic strategies utilized in the setting of acquired resistance to EGFR tyrosine kinase inhibitors.
    Yu HA; Riely GJ; Lovly CM
    Clin Cancer Res; 2014 Dec; 20(23):5898-907. PubMed ID: 25303979
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacological background of EGFR targeting.
    Castillo L; Etienne-Grimaldi MC; Fischel JL; Formento P; Magné N; Milano G
    Ann Oncol; 2004 Jul; 15(7):1007-12. PubMed ID: 15205192
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Small molecule inhibitors targeting the EGFR/ErbB family of protein-tyrosine kinases in human cancers.
    Roskoski R
    Pharmacol Res; 2019 Jan; 139():395-411. PubMed ID: 30500458
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Irreversible multitargeted ErbB family inhibitors for therapy of lung and breast cancer.
    Subramaniam D; He AR; Hwang J; Deeken J; Pishvaian M; Hartley ML; Marshall JL
    Curr Cancer Drug Targets; 2015; 14(9):775-93. PubMed ID: 25435079
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Molecular-Targeted Therapies for Epidermal Growth Factor Receptor and Its Resistance Mechanisms.
    Yamaoka T; Ohba M; Ohmori T
    Int J Mol Sci; 2017 Nov; 18(11):. PubMed ID: 29140271
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Therapeutic targeting of epidermal growth factor receptor in human cancer: successes and limitations.
    Wykosky J; Fenton T; Furnari F; Cavenee WK
    Chin J Cancer; 2011 Jan; 30(1):5-12. PubMed ID: 21192840
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeting the EGF/HER Ligand-Receptor System in Cancer.
    Esparís-Ogando A; Montero JC; Arribas J; Ocaña A; Pandiella A
    Curr Pharm Des; 2016; 22(39):5887-5898. PubMed ID: 27426127
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The ErbB/HER family of protein-tyrosine kinases and cancer.
    Roskoski R
    Pharmacol Res; 2014 Jan; 79():34-74. PubMed ID: 24269963
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Epidermal growth factor receptor targeting in cancer: a review of trends and strategies.
    Yewale C; Baradia D; Vhora I; Patil S; Misra A
    Biomaterials; 2013 Nov; 34(34):8690-707. PubMed ID: 23953842
    [TBL] [Abstract][Full Text] [Related]  

  • 12. EGF-R small inhibitors and anti-EGF-R antibodies: advantages and limits of a new avenue in anticancer therapy.
    Caraglia M; Marra M; Meo G; Addeo SR; Tagliaferri P; Budillon A
    Recent Pat Anticancer Drug Discov; 2006 Jun; 1(2):209-22. PubMed ID: 18221038
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeting the epidermal growth factor receptor in non-small cell lung cancer cells: the effect of combining RNA interference with tyrosine kinase inhibitors or cetuximab.
    Chen G; Kronenberger P; Teugels E; Umelo IA; De Grève J
    BMC Med; 2012 Mar; 10():28. PubMed ID: 22436374
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Epidermal growth factor receptor as a therapeutic target in glioblastoma.
    Kalman B; Szep E; Garzuly F; Post DE
    Neuromolecular Med; 2013 Jun; 15(2):420-34. PubMed ID: 23575987
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Natural tyrosine kinase inhibitors acting on the epidermal growth factor receptor: Their relevance for cancer therapy.
    Liang Y; Zhang T; Zhang J
    Pharmacol Res; 2020 Nov; 161():105164. PubMed ID: 32846211
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Targeting epidermal growth factor receptor and its downstream signaling pathways by natural products: A mechanistic insight.
    Damare R; Engle K; Kumar G
    Phytother Res; 2024 May; 38(5):2406-2447. PubMed ID: 38433568
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeting EGFR and IGF 1R: a promising combination therapy for metastatic cancer.
    Singh I; Amin H; Rah B; Goswami A
    Front Biosci (Schol Ed); 2013 Jan; 5(1):231-46. PubMed ID: 23277048
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Resistance to anti-EGFR therapies in metastatic colorectal cancer: underlying mechanisms and reversal strategies.
    Zhou J; Ji Q; Li Q
    J Exp Clin Cancer Res; 2021 Oct; 40(1):328. PubMed ID: 34663410
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A Third Shot at EGFR: New Opportunities in Cancer Therapy.
    Guardiola S; Varese M; Sánchez-Navarro M; Giralt E
    Trends Pharmacol Sci; 2019 Dec; 40(12):941-955. PubMed ID: 31706618
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A review on progression of epidermal growth factor receptor (EGFR) inhibitors as an efficient approach in cancer targeted therapy.
    Ayati A; Moghimi S; Salarinejad S; Safavi M; Pouramiri B; Foroumadi A
    Bioorg Chem; 2020 Jun; 99():103811. PubMed ID: 32278207
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.